Loading
A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT06357533 by AstraZeneca, with 675 participants planned, started 2024-04-11 and due to reach its primary completion in 2029-12-28. Interventions recorded: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Rilvegostomig, PD-L1-high non-small-cell lung cancer without a driver mutation, AstraZeneca, Pembrolizumab.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Datopotamab deruxtecan, PD-L1-high non-small-cell lung cancer without a driver mutation, Small-cell lung cancer, Pembrolizumab.
Shares Rilvegostomig, Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Pembrolizumab.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Rilvegostomig, Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).